Education
About Us
Working with TipRanks
Follow Us
Biotest AG (CH:BIO)
:BIO
Total Valuation
Biotest has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Biotest has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biotest’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 4.18%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.18%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee291.06K
Profits Per Employee10.58K
Employee Count2,495
Asset Turnover0.51
Inventory Turnover1.05
Valuation Ratios
The current PE Ratio of Biotest is 58.05. Biotest’s PEG ratio is -0.97.
PE Ratio58.05
PS Ratio―
PB Ratio2.97
Price to Fair Value2.89
Price to FCF42.73
Price to Operating Cash Flow25.90
PEG Ratio-0.97
Income Statement
In the last 12 months, Biotest had revenue of 726.20M and earned 26.40M in profits. Earnings per share was 0.71.
Revenue726.20M
Gross Profit223.80M
Operating Income94.50M
Pretax Income46.50M
Net Income26.40M
EBITDA120.40M
Earnings Per Share (EPS)0.71
Cash Flow
In the last 12 months, operating cash flow was 60.90M and capital expenditures 0.00, giving a free cash flow of 32.20M billion.
Operating Cash Flow60.90M
Free Cash Flow32.20M
Free Cash Flow per Share―
Dividends & Yields
Biotest pays an annual dividend of CHF0.036, resulting in a dividend yield of 0.1%
Dividend Per ShareCHF0.036
Dividend Yield0.1%
Payout Ratio5.84%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Biotest upcoming earnings date is Aug 4, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 4, 2025
Ex-Dividend DateMay 08, 2024
Financial Position
Biotest as a current ratio of 5.06, with Debt / Equity ratio of 112.53%
Current Ratio5.06
Quick Ratio2.06
Debt to Market Cap0.35
Net Debt to EBITDA4.06
Interest Coverage Ratio2.84
Taxes
In the past 12 months, Biotest has paid 20.20M in taxes.
Income Tax20.20M
Effective Tax Rate0.43
Enterprise Valuation
Biotest EV to EBITDA ratio is 16.79, with an EV/FCF ratio of 62.80.
EV to Sales2.78
EV to EBITDA16.79
EV to Free Cash Flow62.80
EV to Operating Cash Flow33.20
Balance Sheet
Biotest has €119.50M in cash and marketable securities with €597.20M in debt, giving a net cash position of €477.70M billion.
Cash & Marketable Securities€119.50M
Total Debt€597.20M
Net Cash€477.70M
Net Cash Per Share―
Tangible Book Value Per Share€13.82
Margins
Gross margin is 30.82%, with operating margin of 13.01%, and net profit margin of 3.64%.
Gross Margin30.82%
Operating Margin13.01%
Pretax Margin6.40%
Net Profit Margin3.64%
EBITDA Margin16.58%
EBIT Margin10.99%
Analyst Forecast
The average price target for Biotest is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―